Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard, +547

European Journal of Cancer

Solid Cancer PatientsCancer EpidemiologyDisease Risk AssessmentMedicineEpidemiology Of Cancer +10

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Maxime Ronot, Mohamed Bouattour, Johanna Wassermann, +8

The Oncologist

Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study

Elisé G. Kaboré, Charles Guénancia, Inês Vaz-Luís, +17

PLoS Medicine

Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas

Johanna Wassermann, Marie‐Odile Bernier, Jean‐Philippe Spano, +6

The Oncologist

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

Manuel Rodrigues, Julien Péron, Jean‐Sébastien Frenel, +7

Annals of Oncology

Breast OncologyAdjuvant Trastuzumab-based ChemotherapyMedicineImmunologyBreast Cancer +4

Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer

Johanna Wassermann, Shari Gelber, Shoshana M. Rosenberg, +7

Cancer

Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer

Françoise Borson‐Chazot, Emmanuelle Dantony, F. Illouz, +15

Thyroid

Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network

Arnaud Jannin, Fabiola Giudici, Christelle de la Fouchardière, +21

Thyroid

Body weight and return to work among survivors of early-stage breast cancer

Antonio Di Meglio, Gwenn Menvielle, Agnès Dumas, +18

ESMO Open

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

Arlene Chan, Manuel Ruíz‐Borrego, Gavin Marx, +19

The Breast